| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLE |
National Institute for Medical Research (L.M., C.M., K.M., D.C., J.-B.M., I.C.A.F.R., A.K.S.), Mill Hill, London NW7 1AA, United Kingdom; Department of Human Anatomy and Genetics (H.C.), Oxford OX1 3QX, United Kingdom; and Department of Pediatrics (J.A.P.), Vanderbilt University School of Medicine, Nashville, Tennessee 37235
Address all correspondence and requests for reprints to: Professor Iain C. A. F. Robinson, Division of Molecular Neuroendocrinology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom. E-mail: irobins{at}nimr.mrc.ac.uk.
Autosomal dominant GH deficiency type II (IGHDII) is often associated with mutations in the human GH gene (GH1) that give rise to products lacking exon-3 (
exon3hGH). In the heterozygous state, these act as dominant negative mutations that prevent the release of human pituitary GH (hGH). To determine the mechanisms of these dominant negative effects, we used a combination of transgenic and morphological approaches in both in vitro and in vivo models. Rat GC cell lines were generated expressing either wild-type GH1 (WT-hGH-GC) or a genomic GH1 sequence containing a G->A transition at the donor splice site of IVS3 (
exon3hGH-GC). WT-hGH-GC cells grew normally and produced equivalent amounts of human and rGH packaged in dense-cored secretory vesicles (SVs). In contrast,
exon3hGH-GC cells showed few SVs but accumulated secretory product in amorphous cytoplasmic aggregates. They produced much less rGH and grew more slowly than WT-hGH-GC cells. When cotransfected with an enhanced green fluorescent protein construct (GH-eGFP), which copackages with GH in SVs, WT-hGH-GC cells showed normal electron microscopy morphology and SV movements, tracked with total internal reflectance fluorescence microscopy. In contrast, coexpression of
exon3hGH with GH-eGFP abolished the vesicular targeting of GH-eGFP, which instead accumulated in static aggregates. Transgenic mice expressing
exon3hGH in somatotrophs showed an IGHD-II phenotype with mild to severe pituitary hypoplasia and dwarfism, evident at weaning in the most severely affected lines. Hypothalamic GHRH expression was up-regulated and somatostatin expression reduced in
exon3hGH transgenic mice, consistent with their profound GHD. Few SVs were detectable in the residual pituitary somatotrophs in
exon3hGH transgenic mice, and these cells showed grossly abnormal morphology. A low copy number transgenic line showed a mild effect relatively specific for GH, whereas two severely affected lines with higher transgene copy numbers showed early onset, widespread pituitary damage, macrophage invasion, and multiple hormone deficiencies. These new in vitro and in vivo models shed new light on the cellular mechanisms involved in IGHDII, as well as its phenotypic consequences in vivo.
This article has been cited by other articles:
![]() |
N. Shariat, R. C. C. Ryther, J. A. Phillips III, I. C. A. F. Robinson, and J. G. Patton Rescue of Pituitary Function in a Mouse Model of Isolated Growth Hormone Deficiency Type II by RNA Interference Endocrinology, February 1, 2008; 149(2): 580 - 586. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Osborne, P. J. Wen, C. Boucheron, H. N. Nguyen, M. Hayakawa, H. Kaizawa, P. J. Parker, N. Vitale, and F. A. Meunier PIKfyve Negatively Regulates Exocytosis in Neurosecretory Cells J. Biol. Chem., February 1, 2008; 283(5): 2804 - 2813. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Petkovic, D. Lochmatter, J. Turton, P. E. Clayton, P. J. Trainer, M. T. Dattani, A. Eble, I. C. Robinson, C. E. Fluck, and P. E. Mullis Exon Splice Enhancer Mutation (GH-E32A) Causes Autosomal Dominant Growth Hormone Deficiency J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4427 - 4435. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. I Iliev, N. E Wittekindt, M. B Ranke, and G. Binder In vitro analysis of hGH secretion in the presence of mutations of amino acids involved in zinc binding J. Mol. Endocrinol., August 1, 2007; 39(2): 163 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Salemi, S. Yousefi, D. Lochmatter, A. Eble, J. Deladoey, I. C. A. F. Robinson, H.-U. Simon, and P. E. Mullis Isolated Autosomal Dominant Growth Hormone Deficiency: Stimulating Mutant GH-1 Gene Expression Drives GH-1 Splice-Site Selection, Cell Proliferation, and Apoptosis Endocrinology, January 1, 2007; 148(1): 45 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P G Turton, C. R Buchanan, I. C A F Robinson, S. J B Aylwin, and M. T Dattani Evolution of gonadotropin deficiency in a patient with type II autosomal dominant GH deficiency Eur. J. Endocrinol., December 1, 2006; 155(6): 793 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Vivenza, L. Guazzarotti, M. Godi, D. Frasca, B. di Natale, P. Momigliano-Richiardi, G. Bona, and M. Giordano A Novel Deletion in the GH1 Gene Including the IVS3 Branch Site Responsible for Autosomal Dominant Isolated Growth Hormone Deficiency J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 980 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Salemi, S. Yousefi, K. Baltensperger, I. C A F Robinson, A. Eble, D. Simon, P. Czernichow, G. Binder, E. Sonnet, and P. E Mullis Variability of isolated autosomal dominant GH deficiency (IGHD II): impact of the P89L GH mutation on clinical follow-up and GH secretion Eur. J. Endocrinol., December 1, 2005; 153(6): 791 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Le Tissier, D. F. Carmignac, S. Lilley, A. K. Sesay, C. J. Phelps, P. Houston, K. Mathers, C. Magoulas, D. Ogden, and I. C. A. F. Robinson Hypothalamic Growth Hormone-Releasing Hormone (GHRH) Deficiency: Targeted Ablation of GHRH Neurons in Mice Using a Viral Ion Channel Transgene Mol. Endocrinol., May 1, 2005; 19(5): 1251 - 1262. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Mullis, I. C. A. F. Robinson, S. Salemi, A. Eble, A. Besson, J.-M. Vuissoz, J. Deladoey, D. Simon, P. Czernichow, and G. Binder Isolated Autosomal Dominant Growth Hormone Deficiency: An Evolving Pituitary Deficit? A Multicenter Follow-Up Study J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2089 - 2096. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. I. Iliev, N. E. Wittekindt, M. B. Ranke, and G. Binder Structural Analysis of Human Growth Hormone with Respect to the Dominant Expression of Growth Hormone (GH) Mutations in Isolated GH Deficiency Type II Endocrinology, March 1, 2005; 146(3): 1411 - 1417. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E Mullis Genetic control of growth Eur. J. Endocrinol., January 1, 2005; 152(1): 11 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. C. Ryther, A. S. Flynt, B. D. Harris, J. A. Phillips III, and J. G. Patton GH1 Splicing Is Regulated by Multiple Enhancers Whose Mutation Produces a Dominant-Negative GH Isoform That Can Be Degraded by Allele-Specific Small Interfering RNA (siRNA) Endocrinology, June 1, 2004; 145(6): 2988 - 2996. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. E. Meyer, D. Korthaus, W. Jagla, E. Cornali, J. Grosse, H. Fuchs, M. Klingenspor, S. Roemheld, M. Tschop, G. Heldmaier, et al. A Novel Missense Mutation in the Mouse Growth Hormone Gene Causes Semidominant Dwarfism, Hyperghrelinemia, and Obesity Endocrinology, May 1, 2004; 145(5): 2531 - 2541. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Balthasar, P.-F. Mery, C. B. Magoulas, K. E. Mathers, A. Martin, P. Mollard, and I. C. A. F. Robinson Growth Hormone-Releasing Hormone (GHRH) Neurons in GHRH-Enhanced Green Fluorescent Protein Transgenic Mice: A Ventral Hypothalamic Network Endocrinology, June 1, 2003; 144(6): 2728 - 2740. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |